RELEARN
Summary
This study examines how people's motor learning may differ after a stroke. It is also important to retain motor learning so we examine people's memory/retention of the tasks. This study also examines sensory and motor learning differences of healthy controls of all ages to gather if there are differences as we age. We utilize a robotics exoskeleton called a KINARM to examine the upper limb mobility of participants. During the study you will complete some reaching tasks and games in the KINARM. Our hope is to better understand motor learning of the general population and of those suffering from a stroke so that in the future we may be able to cater rehabilitation to each individual.
Eligibility
Eligible ages: 18 to 100
Accepts healthy participants: Yes
Inclusion criteria:
Healthy Controls
- people 18 years and older
Exclusion criteria:
Healthy Controls
- no current concussion
- no significant upper limb impairment
- no neurological or orthopedic conditions
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
please contact us by email or phone if you wish to participate. email: relearn@ucalgary.ca phone: 403-944-4050
Principal investigator:
Tyler Cluff
Clinical trial:
Yes
REB-ID:
REB21-0441